About the Team

Procyrion 's team of experienced life science entrepreneurs, engineers, cardiologists and heart failure experts is addressing the unmet clinical needs of heart failure patients by developing innovative, safe percutaneous mechanical circulatory support ( pMCS ) devices.

honor

In July 2019 , Procyrion received FDA Breakthrough Device designation for the Aortix ™ System .

Financing

In February 2013 , Procyrion completed its Series A financing of US$ 2.9 million , and the investor was not disclosed.

In December 2014 , Procyrion completed its A+ round of financing with an amount of US$650,000 , and the investor was not disclosed.

In July 2015 , Procyrion completed Pre-B financing of US $ 5.2 million , with the investor being Houston Angel Network .

In October 2015 , Procyrion completed its Series B financing with a total amount of US$ 10 million , and the investor was Scientific Health Development Partners .

In February 2018 , Procyrion completed its Series C financing with a total amount of US$ 16 million , and the investors included Fannin Partners and Scientific Health Development .

In July 2019 , Procyrion received $ 30 million in Series D financing, which was led by Bluebird Ventures , Fannin Partners , and Scientific Health Development . The funds from this round of financing will be used for clinical trials of AORTIX percutaneous blood pumps to treat patients with heart failure.

References